Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxis International (US) gets drug resistance test approval:

This article was originally published in Clinica

Executive Summary

Oxis International (US) has gained US FDA 510(k) approval for its bacterial antibiotic resistance assay, beta-lactamase rapid enzyme-detection disc. The beta-L-Red discs use Oxis' proprietary compound, cefesone, to detect the production of beta lactamase, one of the most common resistance mechanisms. The company says the discs can detect resistance in 15 seconds to an hour, compared with 24 hours for microbiology-lab testing.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT091771

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel